OR WAIT null SECS
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
PCI has divulged that it is making significant investment at its site near Dublin, Ireland to strengthen its position globally and to ensure pharmaceutical supply is uninterrupted for its customers after Brexit.
PCI has divulged that it is making significant investment at its site near Dublin, Ireland to strengthen its position globally and to ensure pharmaceutical supply is uninterrupted for its customers after Brexit, which is set to happen on Oct. 31, 2019.
The investment will be used to build a dedicated clinical facility that will, once completed, provide more than 75,000 sq. ft. of space to the business, which will be used as a center for primary and secondary packaging, storage, logistics, and distribution. Forming a part of the company’s overall global expansion plans, the new Irish facility will increase capabilities and capacity for the clinical services business.
“Our growth strategy is focused on the continued expansion of our global network to support growing demand from our customers and providing a solution for Brexit through ongoing investment in capacity, capability expansion and talent,” said PCI chief executive officer Salim Haffar in an Aug. 27, 2019 press release. “We are very pleased with our team’s progress in expanding our global footprint as we partner with our customers in the shared goal of improving patients’ lives.”
Source: PCI